277 related articles for article (PubMed ID: 19169956)
1. BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle PA; Kufer P; Bargou R
Curr Opin Mol Ther; 2009 Feb; 11(1):22-30. PubMed ID: 19169956
[TBL] [Abstract][Full Text] [Related]
2. Bispecific T-cell engaging antibodies for cancer therapy.
Baeuerle PA; Reinhardt C
Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
[TBL] [Abstract][Full Text] [Related]
3. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
Offner S; Hofmeister R; Romaniuk A; Kufer P; Baeuerle PA
Mol Immunol; 2006 Feb; 43(6):763-71. PubMed ID: 16360021
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA; Kufer P; Lutterbüse R
Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
[TBL] [Abstract][Full Text] [Related]
5. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
8. Role of anti-CTLA-4 therapies in the treatment of cancer.
Abrams SI
Curr Opin Mol Ther; 2004 Feb; 6(1):71-7. PubMed ID: 15011783
[TBL] [Abstract][Full Text] [Related]
9. Diabodies: molecular engineering and therapeutic applications.
Wu C
Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
[TBL] [Abstract][Full Text] [Related]
10. Targeting T cells to tumor cells using bispecific antibodies.
Frankel SR; Baeuerle PA
Curr Opin Chem Biol; 2013 Jun; 17(3):385-92. PubMed ID: 23623807
[TBL] [Abstract][Full Text] [Related]
11. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
13. The new face of bispecific antibodies: targeting cancer and much more.
Lum LG; Davol PA; Lee RJ
Exp Hematol; 2006 Jan; 34(1):1-6. PubMed ID: 16413384
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies engage T cells for antitumor immunotherapy.
Choi BD; Cai M; Bigner DD; Mehta AI; Kuan CT; Sampson JH
Expert Opin Biol Ther; 2011 Jul; 11(7):843-53. PubMed ID: 21449821
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer.
Kershaw MH; Trapani JA; Smyth MJ
Ther Immunol; 1995 Jun; 2(3):173-81. PubMed ID: 8885135
[TBL] [Abstract][Full Text] [Related]
16. Bi-specific antibody therapy for the treatment of cancer.
Withoff S; Helfrich W; de Leij LF; Molema G
Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4: negative regulator of the immune response and a target for cancer therapy.
Keilholz U
J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542
[TBL] [Abstract][Full Text] [Related]
18. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
[TBL] [Abstract][Full Text] [Related]
19. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8
Kim A; Han CJ; Driver I; Olow A; Sewell AK; Zhang Z; Ouyang W; Egen JG; Yu X
J Immunol; 2019 Aug; 203(4):1076-1087. PubMed ID: 31253728
[TBL] [Abstract][Full Text] [Related]
20. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
